Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Sean Wharton; Melanie Davies; Dror Dicker; Ildiko Lingvay; Ofri Mosenzon; Domenica M. Rubino; Sue D. Pedersen

doi:10.1080/00325481.2021.2002616

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Sean Wharton, Melanie Davies, Dror Dicker, Ildiko Lingvay, Ofri Mosenzon, Domenica M. Rubino, Sue D. Pedersen

Research output: Contribution to journal › Comment/debate › peer-review

46 Scopus citations

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.

Original language	English (US)
Pages (from-to)	14-19
Number of pages	6
Journal	Postgraduate medicine
Volume	134
Issue number	1
DOIs	https://doi.org/10.1080/00325481.2021.2002616
State	Published - 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1080/00325481.2021.2002616

Cite this

@article{7ddbeec11c5c47ccb9c375a5bba24f93,

title = "Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice",

abstract = "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.",

author = "Sean Wharton and Melanie Davies and Dror Dicker and Ildiko Lingvay and Ofri Mosenzon and Rubino, {Domenica M.} and Pedersen, {Sue D.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2022",

doi = "10.1080/00325481.2021.2002616",

language = "English (US)",

volume = "134",

pages = "14--19",

journal = "Postgraduate medicine",

issn = "0032-5481",

publisher = "Medquest Communications LLC",

number = "1",

}

TY - JOUR

T1 - Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity

T2 - recommendations for clinical practice

AU - Wharton, Sean

AU - Davies, Melanie

AU - Dicker, Dror

AU - Lingvay, Ildiko

AU - Mosenzon, Ofri

AU - Rubino, Domenica M.

AU - Pedersen, Sue D.

PY - 2022

Y1 - 2022

N2 - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.

AB - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.

UR - http://www.scopus.com/inward/record.url?scp=85120340410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120340410&partnerID=8YFLogxK

U2 - 10.1080/00325481.2021.2002616

DO - 10.1080/00325481.2021.2002616

M3 - Comment/debate

C2 - 34775881

AN - SCOPUS:85120340410

SN - 0032-5481

VL - 134

SP - 14

EP - 19

JO - Postgraduate medicine

JF - Postgraduate medicine

IS - 1

ER -

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this